Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02376920Completed

5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes

Role: lead

NCT02355574Terminated

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

Role: lead

NCT02355587Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes

Role: lead

NCT02407561Terminated

Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

Role: lead

All 4 trials loaded